Avenir Complete Post-Market Clinical Follow-Up Study

Inclusion Criteria:

• Patient is at least 20 years old or older and skeletally mature.
• Advanced wear of the joint due to degenerative, post-traumatic or rheumatic diseases;
• Failed previous hip surgery including
• Joint reconstruction (osteotomy)
• Arthrodesis
• Hemi-arthroplasty or total hip replacement (THR)
• Acute traumatic fracture of the femoral head or neck;
• Avascular necrosis of the femoral head.
• Patients capable of understanding the surgeon's explanations and following hisinstructions, able and willing to participate in the follow-up program and who gaveconsent to take part in the study;

Exclusion Criteria:

• Acute, chronic, local, or systemic infections;
• Severe muscular, neural, or vascular diseases that endanger the limbs involved;
• Lack of bony structures proximal or distal to the joint, so that good Inclusioncriteria
• Patient is at least 20 years old or older and skeletally mature.
• Advanced wear of the joint due to degenerative, post-traumatic or rheumatic diseases;
• Failed previous hip surgery including
• Joint reconstruction (osteotomy)
• Arthrodesis
• Hemi-arthroplasty or total hip replacement (THR)
• Acute traumatic fracture of the femoral head or neck;
• Avascular necrosis of the femoral head.
• Patients capable of understanding the surgeon's explanations and following hisinstructions, able and willing to participate in the follow-up program and who gaveconsent to take part in the study; Exclusion criteria
• Acute, chronic, local, or systemic infections;
• Severe muscular, neural, or vascular diseases that endanger the limbs involved;
• Lack of bony structures proximal or distal to the joint, so that good anchorage of theimplant is unlikely or impossible;
• Total or partial absence of the muscular or ligamentous apparatus;
• Any concomitant diseases that can jeopardize the functioning and the success of theimplant;
• Allergy to the implanted material, especially to metal (e.g. cobalt, chromium, nickel,etc.);
• Local bone tumors and/or cysts;
• Pregnancy;
• Skeletal immaturity.
• Patients unwilling or unable to give consent, or to comply with the follow-up program;
• Patients who have any condition that would - in the judgement of the Investigator -place him/her at undue risk or
• interfere with the study;
• Any vulnerable subject:
• a prisoner
• mentally incompetent or unable to understand what participation in the studyentails
• a known alcohol or drug abuser
• anticipated to be non-compliant
• Patients with plans to relocate during the study follow-up period;
• Individuals whose willingness to volunteer in a clinical investigation could be undulyinfluenced by the expectation, whether justified or not, of benefits associated withparticipation or of retaliatory response from senior members of a hierarchy in case ofrefusal to participate;